Partner, GBS Ventures
| Role | Organisation | Sources |
|---|---|---|
| Chairman (former) | Spinifex Pharmaceuticals | GBS Ventures, clinicalleader.com |
| Partner | GBS Ventures | GBS Ventures, GBS Ventures team page |
| GBS Venture Partners Ltd. | clinicalleader.com |
Stories naming Dr Andrew Baker. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
GBS Ventures marks its fourth FDA drug approval as Hatchtech's head lice treatment Xeglyze clears the regulator, recalling earlier wins behind Picato, Synribo and Aridol with Australian biotech firms.
GBS Ventures reports Novartis has agreed to acquire chronic-pain drug developer Spinifex Pharmaceuticals for US$200 million upfront plus milestones, recalling the company's 2005, 2008 and 2014 venture rounds and its Australian investors.
Also GBS Ventures·novartis.com·clinicalleader.com·Startup Daily·Startup Daily·anthillonline.com·@AuManufacturing·materresearch.org.au·Business News Australia